Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × HER2 Positive Metastatic Breast Cancer × pyrotinib × Clear all

Phase

Phase 3 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 HER2-expressing Advanced Solid Tumors 1 HER2 Positive Metastatic Breast Cancer 1 HER-2 Positive Colorectal Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Metastatic 1 Brain Neoplasms 1

Interventions

pyrotinib 1 Lapatinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡